Targeted Correction and Functional Recovery in Achondroplasia Patient-derived iPSCs

Huan Zou[a], Mingfeng Guan[a], Yundong Li[a], Fang Luo[a], Wenyuan Wang[a,*], Yiren Qin[a,b,*]

[a]Interdisciplinary Research Center on Biology and Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai 201210, China.

[b]State Key Laboratory of Oncogenes and Related Genes, Renji-Med X Clinical Stem Cell Research Center, Renji Hospital, School of Medicine and School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai 200127, China.

*Correspondence: Yiren Qin, e-mail: yirenqin@hotmail.com;

Wenyuan Wang, e-mail: wywang@sioc.ac.cn;

Key Words. Achondroplasia, iPSCs, Gene correction, CRISPR-Cas9

ABSTRACT

Achondroplasia (ACH) is the most common genetic form of dwarfism and belongs to dominant monogenetic disorder caused by a gain-of-function point mutation in the transmembrane region of *FGFR3*. Stem cells and gene-editing technology provide us with effective methods and ideas for research and treatment of ACH. Here we generated non-integrated iPSCs from ACH patient-derived skin and urine via Sendai virus and found that the chondrogenic differentiation ability was confined compared with healthy iPSCs. When the mutation of ACH iPSCs was precisely corrected by CRISPR-Cas9, the chondrogenic differentiation ability of them could be restored. Furthermore, these corrected iPSCs displayed pluripotency, maintained normal karyotype, and did not demonstrate off-target indels. Our study may provide important theoretical and experimental basis for the stem cell research and treatment of ACH.

INTRODUCTION

Achondroplasia (ACH), the most common genetic form of short-limb dwarfism, is autosomal dominant monogenetic disorder (MGD) caused by a gain-of-function point mutation in the transmembrane region of fibroblast growth factor receptor 3 (*FGFR3*). There are currently two mutation sites reported - Gly380Arg and Gly375Cys, the former occupies a vast majority of ACH patients [1,2]. Because homozygous ACH patients have a much more severe phenotype and rarely survive [3,4], most of the ACH patients seen are heterozygous mutations. The estimated frequency of ACH is 1 in 25,000 (Male 1/15000), with at least 80% of the cases being sporadic [5]. Like many other MGDs, there are no effective therapeutic methods for ACH even though the

the mutation has been found [1]. Fortunately, stem cell research provides new hope for potential ACH treatments. Patient-specific stem cells can aid scientists in the investigation of specific molecular mechanisms and can be used to screen for the discovery of new drugs [6,7]. In addition, with powerful genome editing tools used, such as clustered regulatory interspaced short palindromic repeat (CRISPR)-Cas9 system [8], mutation can be corrected in ACH stem cells *in vitro*. Through screening and safety assessment in animal models *in vivo*, stem cell transplantation therapy may provide an effective and novel treatment method [6].

In this study, we isolated and cultured skin, urine, and white adipose-derived somatic cells from ACH patients of Gly380Arg mutation. Further we generated non-integrated iPSC lines from skin and urine by Sendai virus. However adipose-derived mesenchymal stem cells (AD-MSCs) could not be reprogrammed to iPSCs. We found the chondrogenic differentiation ability of ACH iPSCs was confined compared with that of healthy iPSCs. When the mutation of ACH iPSCs was precisely corrected by CRISPR-Cas9, the chondrogenic differentiation ability of them was restored. Via cell immunofluorescence, Alkaline Phosphatase (AP) Staining, karyotyping and sequencing analysis, we found these corrected iPSCs continued to keep pluripotency, maintained normal chromosomal number and structure, and didn't display off-target. Our study may provide important theoretical and experimental basis for the stem cell research and treatment of ACH.

MATERIALS AND METHODS

Research Subjects and Ethical Statement

Research subjects in this study included two children and one adult man. Skin and urine samples were obtained from the children. Liposuction was performed on the adult man. All human subject protocols were reviewed and approved by the Ethical Review Board of the Renji Hospital, Shanghai. All subjects gave signed informed consent.

Isolation and Culture of Skin Fibroblasts (SFs)

Skin biopsies were performed by using a sterile 3 mm skin punch from the locally anesthetized lower legs. The skin tissue was cut in smaller pieces, placed in a 6-well plate and allowed to grow for 2 weeks in fibroblast medium (DMEM, 10% fetal bovine serum (FBS), penicillin/streptomycin (P/S) and glutamine). Above regents were all from ThermoFisher.

Culture of Urine-derived Cells (UCs)

The culture of UCs followed the method established by Pei laboratory [9]. Briefly, urine samples were collected into 50 ml tube and were centrifuged at 400 g for 10 minutes. The supernatants were aspirated carefully, and about 1 ml volume at the bottom was kept in the tube. The remaining was resuspended by washing buffer (PBS containing amphotericin B and P/S) and centrifuged

again. After discarding supernatants, the pellets were suspended by 1 ml primary medium. Then the cell suspensions were seeded into 12-well plates coated with gelatin and cultured in cell incubator. The primary medium contained DMEM/Ham's F-12 1:1 (ThermoFisher), 10% FBS, REGM Renal Epithelial Cell Growth Medium SingleQuots Kit (Lonza), amphotericin B (Selleck) and P/S. After 4 days, the medium was carefully changed to proliferation medium (Lonza REBM BulletKit).

Isolation and Culture of AD-MSCs

Adipose biopsy was obtained by liposuction. Isolation and culture of AD-MSCs followed our previous reports [10]. Briefly, adipose tissue was digested with 0.1% type I collagenase (Sigma) in PBS solution on a shaker at 37°C for 1 hour. Cell suspensions were then centrifuged to obtain stromal vascular fraction (SVF). The SVF was suspended and cultured in fibroblast medium.

PCR and Sanger Sequencing

Total genomic DNA was extracted from patient peripheral blood, SFs, UCs, AD-MSCs, and iPSCs by using the Genomic DNA Extraction Kit (TaKaRa). PCR was performed by using Q5 High-Fidelity DNA Polymerase (New England Biolabs, NEB). *FGFR3* primers were

Forward: 5'-AGGAGCTGGTGGAGGCTGA-3',

Reverse: 5'-GGAGATCTTGTGCACGGTGG-3'.

PCR reactions were then purified by using GeneJET Gel Extraction Kit (ThermoFisher) and sequenced by the Genewiz.

Generation of Non-integrated iPSCs

Induction of iPSCs from SFs, UCs, and AD-MSCs was performed by using CytoTune iPS 2.0 Sendai Reprogramming Kit (ThermoFisher). Briefly, approximately 200,000 donor cells were seeded in a 6-well plate to culture. Two days later, cells were transduced with the Reprogramming Kit. 24 hours after transduction, the medium was replaced with fresh medium every other day. On day 8 after transduction, the donor cells were trypsinized and 5000 cells were seeded into a 6-well plate. The media were replaced by E8 (StemCell) every day thereafter. 3-4 weeks after transduction, single cell colonies were picked for expansion and characterization.

Chondrogenic Differentiation of iPSCs

This method referred to report of Tsumaki laboratory [7]. After iPSCs formed high-density cell colonies in E8, the medium was changed to initial chondrogenic medium, including DMEM/F12 (ThermoFisher), 10 ng/ml of Wnt3A (R&D), 10 ng/ml of Activin A (Peprotech), 1% ITS (ThermoFisher), and 1% FBS (ThermoFisher). On day 3, the medium was changed to the basal

medium, including DMEM (ThermoFisher), 1% ITS, 1% FBS, 2 mM L-glutamine, non-essential amino acids, 1mM Napyruvate (ThermoFisher), 50 μg/ml ascorbic acid (Sigma), 10 ng/ml BMP2 (Peprotech), 10 ng/ml TGFβ1 (Peprotech), and 10 ng/ml GDF5 (Peprotech). 10 ng/ml bFGF (Peprotech) was added to the chondrogenic medium from day 3 to day 14. After Day 42, the medium was changed to fibroblast medium.

AP Staining

AP staining was performed by using Vector Blue AP Substrate Kit (Vector). Procedure was conducted in accordance with the instruction.

Design of Single Guide RNAs (sgRNAs) and Construction of Vector

sgRNAs were designed to target point mutation site by using the Guide Design Resouces of Zhang lab (https://zlab.bio/guide-design-resources). Then oligo sgRNAs were annealed and ligated to the pSpCas9(BB)-2A-RFP plasmid which was digested with Bbs I (NEB) enzyme.

Transfection of CRISPR into iPSCs

One million iPSCs were resuspended in 800 μl cold PBS and mixed with targeting and single-stranded oligo DNA nucleotides (ssODNs) donor (5 μg CRISPR targeting plasmid and 40 μg donor). The cells were electroporated using the Human Stem Cell Nucleofector Kit 2 (Lonza) on Nucleofector 2b Device (Lonza). Cells were recovered and re-plated on plates with ROCK inhibitor. 24-48 hours after electroporation, about 5000 RFP positive cells were sorted and seeded into 100 mm plate by BD FACS Aria II. One week later, single colony was pick up and expanded for sequencing analysis.

Off-target Effect Analysis

18 potential “off-target” sites given by Guide Design Resouces were identified. DNA sequencing of PCR products amplified from these sites was performed. The sequences of the primers for off-target sites were listed in Table 1.

Cell Immunofluorescence

iPSCs were fixed in 4% paraformaldehyde solution for 15 minutes at room temperature (RT). Next, they were permeabilized by using 0.1% Triton X-100 in PBS for 20 minutes at RT. After they were blocked for 1 hour in 5% goat serum, the cells were incubated with primary antibodies Nanog (Abcam), SSEA-1 (Millipore), Oct4 (Cell signal), SSEA-4 (Millipore), Sox2 (Abcam), and TRA-1-60 (Abcam) overnight at 4°C. The cells were incubated with a fluorescently coupled secondary antibody for 1 hour at RT, meanwhile the nuclei were stained with 4’,6-diamidino-2-phenylindole (DAPI; Sigma). Images were captured on a Leica confocal microscope.

Karyotyping

The iPSCs were cultured in E8 with 0.1 μg/ml colchicine (ThermoFisher) for 2 hours. After medium being removed, they were incubated in 0.56% potassium chloride for 40 minutes, then fixed in methanol: acetic acid (3:1 in volume) overnight. The cell suspensions were dropped onto cool slides and stained with Giemsa (ThermoFisher) for 15 minutes. Finally, chromosome analysis was performed under the karyotyping image analysis system. More than 15 metaphase spreads of each sample were analyzed.

RNA Extraction and RT-qPCR

Total RNAs were extracted from whole cells using TRIzol RNA Isolation Reagents (Thermofisher). cDNA was synthesized from total RNA with a Hifair II 1st Strand cDNA Synthesis Kit (Yeasen) for qPCR (TB Green Premix Ex Taq kit, TakaRa). PCR procedure was carried out according to the kit instructions. Primers used were as follows:

SOX9 F: AGACCTTTGGGCTGCCTTAT
R: TAGCCTCCCTCACTCCAAGA
COL2A1 F: TTTCCCAGGTCAAGATGGTC
R: CTTCAGCACCTGTCTCACCA
ACAN F: AGGCAGCGTGATCCTTACC
R: GGCCTCTCCAGTCTCATTCTC
β-ACTIN F: TGGCACCACACCTTCTACAATGAGC
R: GCACAGCTTCTCCTTAATGTCACGC

EdU Staining

We used BeyoClick EdU-594 kit (Beyotime) for staining. Briefly, cells were incubated for 24 hours in 10 μM EdU medium at 37ºC in incubator. After EdU solution was removed, the cells were washed twice in PBS. Then they were fixed and performed immunocytochemistry procedure.

Safranin O staining

Safranin O staining Kit (ScienCell Research Laboratories, Inc. #8384) was used to perform this experiment. Procedure was in accordance with the instruction.

RESULTS

Identification of ACH Patients and Isolation and Culture of Somatic Cells

We recruited three ACH patient donors, including an 8-year-old girl, a 7-year-old boy and one 37-year-old adult man. Genetic identification was confirmed by DNA genome sequencing, and the donors are all heterozygous mutations of a G-A transition at nucleotide 1138 of the cDNA of

FGFR3 (Fig. 1A-1C). In addition, their clinical phenotypes are consistent with the NIH-defined characteristics, such as short arms and legs, enlarged head, and prominent forehead. We punched skin tissue and collected urine from the two children to culture SFs and UCs. Via liposuction, we obtained adipose tissue from the adult man to culture AD-MSCs. After the small pieces of skins were placed and cultured in the dish for 2 weeks, SFs gradually climbed out to begin to proliferate (Fig. 1D, 1E). After urine-derived pellets were cultured for one week, UCs formed colonies and showed epithelial cell morphology (Fig. 1F, 1G). After SVF from adipose tissue was seeded and cultured for 2-3 days, AD-MSCs grew out and exhibited a typical fibroblast-like morphology (Fig. 1H, 1I).

Generation of Non-integrated iPSCs from ACH Patients

To generate non-integrated iPSCs from patient-derived somatic cells, we used Sendai virus to transfect cells. Three weeks after transduction of SFs and UCs, lots of ES cell-like colonies appeared (Fig. 2A, 2B). After picking up and expanding single colony, we established non-integrated iPSC lines from skin and urine (Fig. 2C, 2D). These iPSCs expressed pluripotent protein - NANOG, OCT4, SOX2, SSEA-4, and TRA1-60, while didn't express SSEA-1 (Fig. 2G). They also showed AP positive (Fig. 2H). In addition, karyotyping analysis indicated that they maintained normal chromosomal number and structure (Fig. 2I). However, it was surprised that iPSCs could not be generated from AD-MSCs. Although small and unhealthy colonies could appear (Fig. 2E), they gradually became apoptotic and eventually died (Fig. 2F).

Chondrogenic Differentiation Capability of ACH iPSCs

To figure out whether the mutations of ACH iPSCs would affect their function, we performed detection of their chondrogenic differentiation capability. We simultaneously used healthy human iPSCs and ACH iPSCs to induce chondrogenic differentiation in a multi-step method (Fig. 3A). We found that the chondrogenic clusters from ACH iPSCs were less and smaller than those from healthy iPSCs (Fig. 3B). By Safranin O staining, we discovered the cartilage tissue derived from ACH iPSCs showed less and weaker positive areas and lower cartilage density than that from healthy iPSCs (Fig. 3C). These results indicated that the cartilage tissue derived from ACH iPSCs could produce less and thinner cartilaginous extracellular matrix. RT-qPCR results also exhibited that cartilage tissue derived from ACH iPSCs expressed lower chondrocyte-specific genes SOX9 and COL2A1 (Fig. 3D). Our results suggested the chondrogenic differentiation ability of ACH iPSCs was confined compared with that of healthy iPSCs.

Gene Correction of ACH iPSCs by CRISPR-Cas9

To design sgRNAs, we input 64 bp DNA sequences of ACH *FGFR3* around the point mutation site into Guide Design Resouces. More than 10 sgRNAs were generated and we selected the sg2RNA of highest score for use (Fig. 4A). To correct the point mutation in ACH iPSCs, we used 131 nucleotides as the homology arm ssODNs donor which contained the point mutation site (Fig. 4A). 24-48 hours after CRISPR-sgRNAs and ssODNs were transected into ACH iPSCs, we detected the transfection efficiency by FACS. The RFP positive ratio was 3.6% (Fig. 4B). By sequencing analysis of 32 expanded single RFP positive colonies, we found two completely corrected cell lines (Fig. 4C, 4D), and the efficiency was 7.7%. We analyzed the two corrected iPSC lines and found they expressed pluripotent protein - NANOG, OCT4, SOX2, SSEA-4 and TRA1-60, while didn't express SSEA-1 (Fig. 4E). They also indicated AP positive (Fig. 4F). The karyotyping analysis verified they maintained normal chromosomal number and structure (Fig. 4G). Sequencing analysis of potential offtarget sites given by Guide Design Resouces showed that no off-target indels were identified.

Functional Recovery of Corrected ACH iPSCs

To detect whether the function of corrected ACH iPSCs was restored, we performed the detection of chondrogenic differentiation ability of them. Through morphological observation, we found that chondrogenic clusters from corrected iPSCs obviously increased compared with those from uncorrected cells (Fig. 5A, 5B). Our EdU cell proliferation assay displayed corrected cells possessed higher positive radio than uncorrected cells (Fig. 5C-5E). Via Safranin O staining, we found there were more and stronger positive areas in cartilage tissue from corrected ACH iPSCs than that from uncorrected cells (Fig. 5F, 5G). Compared with cartilage tissue from ACH iPSCs, RT-qPCR results also revealed cartilage tissue from corrected ACH iPSCs expressed higher chondrocyte-specific genes - SOX9, ACAN and COL2A1 (Fig. 5H). These results suggested the chondrogenic differentiation ability of corrected ACH iPSCs was restored.

DISCUSSION

Whenever about 25,000 children are born, one of them may be an ACH patient [5]. For ACH patients, not only will they lose a lot of opportunities to get education and job because of their short stature, but they also have many complications, such as hydrocephalus, obesity and sleep apnea etc. The older they are, the more serious they will be, which will seriously affect their longevity. The average life expectancy for this cohort was decreased by 15 years compared with the US population [5]. Moreover, the social concern of this disease is very low. At present there are no effective therapeutic methods for ACH. With the rapid development of stem cell biology

and gene-editing technology, the research and treatment of ACH not only show promising, but also provide ideas and experimental basis for the investigation of other MGDs [6].

In this study, we first collected and isolated three different tissue samples from ACH patients to culture somatic cells, including the most commonly used skin, the most easily available urine and a large amount of acquired adipose tissue that can produce multipotent MSCs with chondrogenic differentiation ability. We found that, like skin cells, ACH patient urine-derived cells could be efficiently reprogrammed into iPSCs, which may provide new donor cells for research of MGDs. However, to our surprise, ACH patient-derived AD-MSCs could not be reprogrammed into iPSCs. In fact, previously reported study [11,12] and our unpublished results found that healthy human AD-MSCs could be reprogrammed more efficiently to iPSCs than skin cells. Given ACH is a regeneration dysfunction of MSC-derived chondrocyte disorder caused by *FGFR3* mutation, our results suggested that perhaps the point mutation affected the reprogramming ability of AD-MSCs.

Our initial hypothesis was that point mutations might affect the chondrogenic differentiation ability of ACH iPSCs. Indeed, our experimental results confirmed chondrogenic differentiation ability of ACH iPSCs was confined compared with that of healthy iPSCs. By novel and powerful gene-editing tool - CRISPR-Cas9, we successfully obtained two completely corrected iPSCs lines. The rate of precise homology directed repair was 7.7%, showing an optimistic efficiency comparing with study already reported [13,14]. These corrected iPSCs still displayed pluripotency and maintained normal karyotype. Sequencing analysis of potential offtarget sites suggested no off-target indels were identified. Finally, we detected whether the function of corrected ACH iPSC could be improved. Via chondrogenic differentiation, EdU cell proliferation assay, and RT-qPCR experiments, we found their chondrogenic differentiation ability was indeed restored compared with uncorrected cells.

In summary, our study results of ACH iPSCs *in vitro* provided a solid and important foundation for the further exploration of ACH research and treatment *in vivo*. At present, we are constructing point mutation mouse model of ACH. Next, we will transplant the corrected ACH patient-derived MSCs or chondrocyte precursor cells into the mice to verify their function *in vivo* and explore the effect of this cell replacement therapy to ACH. Although challenges remain, the clinical application of patient-specific stem cells will be pursued through further advances in basic research (Fig. 5).

CONCLUSION

In this study we generated non-integrated iPSCs from ACH patient skin and urine, and found the chondrogenic differentiation ability was limited. When the mutation of ACH iPSCs was precisely

corrected, their function could be restored. These corrected iPSCs displayed pluripotency and maintained normal karyotype, and did not show offtarget. Our study may provide important theoretical and experimental basis for the stem cell research and treatment of ACH in the future.

ACKNOWLEDGEMENTS

This work was funded by grant from the National Natural Science Foundation of China, General Program 31570992 to Q.Y.R. I would like to thank Dr. Wei-Qiang Gao for his helpful discussion in conceiving the project, Dr. Hui Yang for providing pSpCas9(BB)-2A-RFP plasmid, Chikai Zhou and Dr. Erwei Zuo for their helpful discussion in designing sgRNA, Dr. Sushan Luo for skin biopsy. Guangrui Cao for her helpful language modification.

DISCLOSURE OF POTENTIAL CONFLICTS OF INTEREST

There is no potential conflict of interest.

AUTHOR CONTRIBUTIONS

Z.H. performed experiments and analyzed data, G.M.F., L.Y., and L.F. performed experiments; W.W.Y. provided experimental platform and financial support; Q.Y.R. conceived and designed the study, performed experiments, analyzed data, provided financial support and wrote the manuscript.

REFERENCES

1 Shiang R, Thompson LM, Zhu YZ, et al. Mutations in the transmembrane domain of FGFR3 cause the most common genetic form of dwarfism, achondroplasia. Cell 1994;29:335-342.

2 Superti-Furga A, Eich G, Bucher HU, et al. A glycine 375-to-cysteine substitution in the transmembrane domain of the fibroblast growth factor receptor-3 in a newborn with achondroplasia. Eur J Pediatr 1995;154:215-219.

3 Pauli RM, Conroy MM, Langer LO, et al. Homozygous achondroplasia with survival beyond infancy. Am J Med Genet 1983;16:459-473.

4 Hecht JT, Horton WA, Butler IJ, et al. Foramen magnum stenosis in homozygous achondroplasia. Eur J Pediatr 1986;145:545-547.

5 Horton WA, Hall JG, Hecht JT. Achondroplasia. Lancet 2007;370:162-172.

6 Qin Y and Gao WQ. Concise Review: Patient-Derived Stem Cell Research for Monogenic Disorders. Stem Cells 2016;34:44-54.

7 Yamashita A, Morioka M, Kishi H, et al. Statin treatment rescues FGFR3 skeletal dysplasia phenotypes. Nature 2014;513:507- 511

8 Cong L, Ran FA, Cox D, et al. Multiplex genome engineering using CRISPR/Cas systems. *Science*. 2013;339:819-823.

9 Zhou T, Benda C, Duzinger S, et al. Generation of induced pluripotent stem cells from urine. J Am Soc Nephrol 2011;22:1221-1228.

10 Qin Y, Qin J, Zhou C, et al. Generation of embryonic stem cells from mouse adipose-tissue derived cells via somatic cell nuclear transfer. Cell Cycle 2015;14:1282-1290.

11 Sun N, Panetta NJ, Gupta DM, et al. Feeder-free derivation of induced pluripotent stem cells from adult human adipose stem cells. Proc Natl Acad Sci USA 2009;106:15720-15725.

12 Sugii S, Kida Y, Kawamura T, et al. Human and mouse adipose-derived cells support feeder-independent induction of pluripotent stem cells. Proc Natl Acad Sci USA 2010;107:3558-3563.

13 Lin S, Staahl BT, Alla RK, et al. Enhanced homology-directed human genome engineering by controlled timing of CRISPR/Cas9 delivery. Elife 2014;15:e04766.

14 Yang D, Scavuzzo MA, Chmielowiec J, et al. Enrichment of G2/M cell cycle phase in human pluripotent stem cells enhances HDR-mediated gene repair with customizable endonucleases. Sci Rep 2016;18:21264.

FIGURES AND FIGURE LEGENDS



Figure 1. Identification of ACH patients and isolation and culture of somatic cells. **(A-C)** Sequence of three ACH patient donors showed they are all heterozygous mutation of a G-A transition at nucleotide 1138 of the cDNA. **(D, E)** SFs from girl and boy. **(F, G)** UC colonies from girl and boy showed epithelial cell morphology. **(H, I)** AD-MSCs from adult man exhibited a typical fibroblast-like morphology.



Figure 2. Generation of non-integrated iPSCs from ACH patients and characterization of them. **(A, B)** 3 weeks ES cell-like colonies from girl SFs (GF) and boy UCs (BU) after transfection. **(C)** Expanded iPSCs from GF. **(D)** Expanded iPSCs from BU. **(E)** 3 weeks ES cell-like colonies from AD-MSCs after transfection, they were small and unhealthy. **(F)** Colonies from AD-MSCs gradually became apoptotic and eventually died. **(G)** iPSCs from GF and BU expressed pluripotent protein - NANOG, OCT4, SOX2, SSEA4 and TRA1-60, but didn't express SSEA-1. **(H)** iPSCs from GF and BU showed AP positive. **(I)** iPSCs from GF and BU indicated normal chromosomal number and structure.



Figure 3. Chondrogenic differentiation of ACH iPSCs. **(A)** A multi-step chondrogenic differentiation method. **(B)** Chondrogenic clusters from ACH iPSCs were less and smaller than those from healthy iPSCs. **(C)** Safranin O staining displayed there were less and weaker positive areas in cartilage tissue from ACH iPSCs than that from healthy iPSCs. **(D)** RT-qPCR results also exhibited that cartilage tissue derived from ACH iPSCs expressed lower chondrocyte-specific genes SOX9 and COL2A1.



Figure 4. Gene correction of ACH iPSCs by CRISPR-Cas9 and characterization of corrected iPSCs. **(A)** Designed sgRNA and ssODNs around the point mutation site. **(B)** FACS detection showed the RFP positive cells were 3.6%. **(C, D)** Two corrected iPSC lines showed normal DNA sequence. **(E)** Corrected iPSCs expressed NANOG, OCT4, SOX2, SSEA4 and TRA1-60, but didn't express SSEA-1. **(F)** Corrected iPSCs indicated AP positive. **(G)** Corrected iPSCs showed normal chromosomal number and structure.



Figure 5. Chondrogenic differentiation of corrected ACH iPSCs. **(A, B)** Chondrogenic clusters from corrected iPSCs obviously increased compared with the uncorrected cells. **(C-E)** EdU cell proliferation assay indicated corrected iPSCs showed higher positive radio than uncorrected cells. **(F, G)** Safranin O staining illustrated cartilage tissue from corrected ACH iPSCs demonstrated more and stronger positive areas, and higher cartilage density than uncorrected cells. **(H)** RT-qPCR results also revealed that the expression level of chondrocyte-specific genes - SOX9, ACAN and COL2A1 from corrected ACH iPSCs were higher than that of ACH iPSCs.



Figure 6. Diagrammatic strategy of ACH patient-derived stem cell research. Somatic cells can be isolated and cultured from ACH adipose, skin, and urine, and further can be reprogrammed into iPSCs. After gene correction of iPSCs or AD-MSCs via CRISPR-Cas9, they can differentiate into healthy cells, such as MSCs or chondrocyte precursor cells. Then these healthy cells can be transplanted into ACH mouse model to assess their relative safety and therapeutic effects.